EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.60
+0.10 (+4.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.50
Open2.47
Bid2.60 x 2900
Ask2.62 x 1400
Day's Range2.47 - 2.61
52 Week Range0.93 - 2.88
Volume561,630
Avg. Volume281,546
Market Cap193.731M
Beta-1.56
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.58
Trade prices are not sourced from all markets
  • GuruFocus.com9 days ago

    US Stocks Lower on Wednesday

    EyePoint Pharmaceuticals down more than 3% after reporting results

  • EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
    Zacks9 days ago

    EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press9 days ago

    EyePoint Pharmaceuticals: Fiscal 4Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had a loss of 62 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The drug delivery technology company posted revenue ...

  • GlobeNewswire9 days ago

    EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

    -Substantial progress made in the Company’ s accelerated transformation into a commercial entity. -YUTIQ™ PDUFA date of November 5, 2018. -Commercial preparations underway for launch of DEXYCU™ in the ...

  • GlobeNewswire11 days ago

    EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its next Chairman of the Board. As part of this transition, David J. Mazzo, Ph.D., will step-down as Non-Executive Chairman, but will remain on the Board and will continue to serve as Chair of the Compensation Committee. “We are pleased to have Dr. Ando serve as our Chairman of the Board as we continue our transition into a commercial-stage specialty pharmaceuticals company,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • ACCESSWIRE15 days ago

    Healthcare Stocks Take Center Stage In September

    CORAL GABLES, FL / ACCESSWIRE / September 6, 2018 / The healthcare industry has become one of the fastest growing industries in the world. The growing advancements in the industry are steadily contributing towards its market growth. According to the findings of the latest study, expansion in the current market, new product development, and improving operational effectiveness are the top three priorities for the healthcare companies over the next six months.

  • Benzinga15 days ago

    The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...

  • GlobeNewswire16 days ago

    EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and reimbursement through a C-code for DEXYCUTM (dexamethasone intraocular suspension) 9%. DEXYCU is the Company’s U.S. Food and Drug Administration (FDA) approved product for the treatment of postoperative inflammation that is administered as a single intraocular dose at the end of ocular surgery. “The receipt of pass-through status and the assignment of a C-code from CMS marks another important step forward in our commercialization preparation for DEXYCU,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • GlobeNewswire16 days ago

    EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Sept. 05, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results ...

  • EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release
    Zacks18 days ago

    EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release

    EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire24 days ago

    EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 28, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of John Weet, Ph.D. as Senior Vice President, Regulatory Affairs & Quality. Dr. Weet brings to EyePoint over 40 years of experience in regulatory affairs. “We are delighted to welcome Dr. Weet, a proven regulatory affairs executive, to the growing EyePoint team,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to David Price, EyePoint’s newly appointed Chief Financial Officer. The Compensation Committee approved the awards on July 31, 2018 as an inducement material to Mr. Price’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference

    WATERTOWN, Mass., Aug. 02, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that ...

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the Company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience in the healthcare, investment banking and accounting industries.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of twelve month efficacy and safety data supporting the Company's YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Vancouver, BC, Canada. "Data from the Phase 3 program continue to support the potential for YUTIQ™ to serve as an effective and safe therapy in the thousands of patients suffering from noninfectious posterior segment uveitis," said Nancy Lurker, President and Chief Executive Officer.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists

    WATERTOWN, Mass., July 11, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that ...

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr. Ando, the former Chairman of the Board of Novo Nordisk A/S (NVO), a global pharmaceutical company, brings more than 35 years of global drug development and general management experience to EyePoint. “Dr. Ando’s extensive experience across the many facets of the global pharmaceutical industry will undoubtedly be valuable as we transition into a commercial ophthalmic company with our planned U.S. launches of DEXYCU™ and, if approved, YUTIQ™,” said David J. Mazzo, Ph.D., Chairman of the Board of Directors of EyePoint Pharmaceuticals.

  • ACCESSWIRE3 months ago

    EyePoint Pharmaceuticals, Acquisition, NDA and PDUFA Date, Pipeline Update

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. EyePoint has developed three FDA-approved products utilizing its proprietary DurasertTM Technology. The company is utilizing its Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing

    Expected closing of $25.5 million in capital to be used to accelerate EyePoint’ s transformation into a commercial-stage specialty biopharmaceutical company Financing supports two near-term product launches ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Check-Cap and EyePoint Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 25, 2018 / Shares of Check-Cap and EyePoint Pharmaceuticals both experienced some unusual activity in Tuesday trading with both stocks seeing significant gains on high ...

  • Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher?
    Zacks5 months ago

    Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. (EYPT)